AI assistant
NYRADA INC. — Capital/Financing Update 2021
Mar 29, 2021
65469_rns_2021-03-29_c35f9edb-0d9c-4d88-a7a8-aef5492dae39.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [596 x 114] intentionally omitted <==
30 March 2021
Sydney, Australia
Cleansing Statement
Sydney, 30 March 2021 : Nyrada Inc (ASX: NYR), issued further to the Appendix 2A lodged on 29 March 2021:
-
27,706,405 CHESS Depositary Interests (CDIs) from Tranche 1 of Capital Raising Program as announced on 22 March 2021.
-
NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:
-
1 The CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
-
2 As at the date of this notice, NYR has complied with:
-
(a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and
-
(b) Section 674 of the Corporations Act.
-
-
3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.
For and on behalf of the Board,
Yours faithfully,
==> picture [106 x 61] intentionally omitted <==
David Franks
Company Secretary
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.
www.nyrada.com
Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.
Nyrada Inc. Suite 3, Level 4, 828 Pacific Highway GORDON, NSW 2072
ARBN 625 401 818
==> picture [596 x 114] intentionally omitted <==
Investor & Corporate Enquiries: Laura Vize Investor Relations Manager T: 0417 026 056 E: [email protected]
Company Secretary: David Franks T: 02 8072 1400 E: [email protected]
Media Enquiries:
Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: [email protected]
Forward-Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.
Nyrada Inc. Suite 3, Level 4, 828 Pacific Highway GORDON, NSW 2072
ARBN 625 401 818